Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.
1. A method for treating a cancer in a patient,
comprising administering to the patient:
a Toll-like receptor agonist,
lymphocyte activation gene 3 (LAG-3) protein or a fusion protein of an extracellular domain of LAG-3 protein and IgG, and
an HSP70-derived peptide consisting of SEQ ID NO: 7 and a GPC3-derived peptide consisting of SEQ ID NO: 16.
2. The method according to claim 1 , wherein the Toll-like receptor agonist is a Toll-like receptor 3 agonist or a Toll-like receptor 9 agonist.
3. The method according to claim 1 , wherein the Toll-like receptor agonist is Poly I:C or a salt thereof.
4. The method according to claim 3 , wherein the Poly I:C is Poly ICLC.
5. A method for inducing an immune response to a cancer cell in a patient, comprising administering to the patient:
a Toll-like receptor agonist, and
lymphocyte activation gene 3 (LAG-3) protein or a fusion protein of an extracellular domain of LAG-3 protein and IgG, and
an HSP70-derived peptide consisting of SEQ ID NO: 7 and a GPC3-derived peptide consisting of SEQ ID NO: 16.